
Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (Catalog # 2078-T4), immobilized onto a microplate, supports the adhesion of the HSB2 human peripheral blood acute lymphoblastic leukemia cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human LILRB2/CD85d/ILT4 Fc Chimera (35 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human LILRB2/CD85d/ILT4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2078). The ND50 is typically 0.3-1.0 µg/mL.